Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Personalis Inc excels in Q4 earnings, eyes growth through strategic focus

Personalis Inc's Q4 2022 earnings call highlighted strong financial performance, strategic focus on MRD, and guidance for 2023 amidst market challenges and opportunities.
The company's strengths in partnerships, product innovation, and financial management position it well for future growth and success in a competitive landscape.
While facing challenges in sample delivery, margin expectations, and operational changes, Personalis Inc is poised to leverage opportunities in partnerships, product launches, and market expansion.
Navigating the evolving landscape with resilience and adaptability, Personalis Inc aims to drive growth, profitability, and innovation in the coming year.

Personalis Inc reports strong Q1 revenue growth and oncology progress

Personalis Inc's Q1 2023 performance showcased revenue growth and progress in oncology.
The company aims to launch NeXT Personal for clinical use by Q4 2023, targeting cancer diagnostics.
Challenges include managing expenses, net loss, and ensuring efficient cash usage for financial goals.

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Publishes New Data Demonstrating Performance & Utility of SHERPA for High-Accuracy Neoantigen Prediction & Cancer Diagnostic Biomarker Devt

Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021. In conjunction with the release, the company will host a conference call and webcast that day at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone

Personalis to Announce Third Quarter Financial Results on November 4, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Expands Leadership Team with Appointment of Robert Bruce, Vice President of Reimbursement

Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement

The stock price of Personalis Inc (NASDAQ: PSNL) increased by over 3.4% today. This is why it happened.

PSNL Stock: Why It Increased Today

ROCHESTER, Minn. & MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Mayo Clinic collaborates with Personalis Inc. to expand cancer genomic testing

Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing

ARK Innovation ETF

Invitae

The CEO of ARK Invest is averaging down on these compelling life-science stocks.

Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarker--Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue 2021 Outlook, Oncology Growth

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth

CRISPR Therapeutics

All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.

Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT PlatformTM is designed to ad

Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarker--Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development

Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development

Personalis' (PSNL) CEO John West on Q2 2021 Results - Earnings Call Transcript

Shares of Personalis (NASDAQ:PSNL) fell 1.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 17.24% year over year to ($0.34), which beat the estimate of ($0.39).

Recap: Personalis Q2 Earnings

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Record quarterly revenue of $21.7 million in the second quarter of 2021 compared with $19.5 million in the second quarter of 2020, an 11% increase Revenue of $8.2 million from biopharma and all other customers, excluding the U.S. Department of Vet

Personalis Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021. About Personalis, Inc. Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and

Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

MENLO PARK, Calif.--(BUSINESS WIRE)-- #Biomarkers--Personalis Publishes Data Demonstrating Novel Composite Biomarker NEOPS, Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Personalis (PSNL) Q2 Earnings Expected to Decline

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone

Personalis to Announce Second Quarter Financial Results on August 4, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Announces NeXT Level Biomarkers Symposium

Personalis Announces NeXT Level Biomarkers Symposium

Personalis, Inc. is a global cancer genomics company offering genomic sequencing and data analytics solutions for comprehensive molecular data analysis for patient-specific cancers and immune responses.

Personalis: Market-Leading Immuno-Oncology Platform Drives Consistent Long-Term Growth

MENLO PARK, Calif.--(BUSINESS WIRE)-- #GenomeSequencing--Personalis Announces Delivery of the 125,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

Personalis Announces Delivery of the 125,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021. Interested parties may access the pre-recorded and archived webcast of the presentation for 90 days following the conference through the “Events” section of Personalis' website at http://investors.personalis.com. About Personalis, Inc. Person

Personalis to Participate at the Oppenheimer MedTech, Tools & Diagnostics Summit

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis, Inc. to Present at Biomarkers Week Online 2021

Personalis, Inc. to Present at Biomarkers Week Online 2021

Personalis, Inc. (PSNL) CEO John West on Q1 2021 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Record quarterly revenue of $20.9 million in the first quarter of 2021 compared with $19.2 million in the first quarter of 2020, a 9% increase Revenue of $7.7 million from biopharma and all other customers, excluding VA MVP, in the first quarter of 2021 compa

Personalis Reports First Quarter 2021 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing programs globally and is curr

News for Personalis Inc Stock (PSNL)